Isoray (NYSEAMERICAN:ISR) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Isoray (NYSEAMERICAN:ISR) from a sell rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated. “

Separately, Northland Securities assumed coverage on Isoray in a research note on Tuesday, September 14th. They set an outperform rating and a $1.25 price objective for the company.

ISR stock opened at $0.39 on Wednesday. The firm has a market cap of $54.88 million, a PE ratio of -7.73 and a beta of 0.93. Isoray has a twelve month low of $0.37 and a twelve month high of $2.81.

Isoray (NYSEAMERICAN:ISR) last released its earnings results on Wednesday, November 10th. The healthcare company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Isoray had a negative return on equity of 9.19% and a negative net margin of 48.05%. The firm had revenue of $2.56 million for the quarter, compared to the consensus estimate of $2.58 million. On average, research analysts forecast that Isoray will post -0.04 EPS for the current year.

Several institutional investors have recently made changes to their positions in ISR. Bank of New York Mellon Corp grew its stake in Isoray by 300.1% in the second quarter. Bank of New York Mellon Corp now owns 99,229 shares of the healthcare company’s stock valued at $80,000 after acquiring an additional 74,426 shares during the period. Bard Associates Inc. grew its stake in Isoray by 40.3% in the second quarter. Bard Associates Inc. now owns 537,400 shares of the healthcare company’s stock valued at $429,000 after acquiring an additional 154,400 shares during the period. Strategic Wealth Advisors Group LLC acquired a new position in Isoray in the second quarter valued at about $38,000. Geode Capital Management LLC grew its stake in Isoray by 13.7% in the second quarter. Geode Capital Management LLC now owns 1,119,070 shares of the healthcare company’s stock valued at $892,000 after acquiring an additional 134,843 shares during the period. Finally, Morgan Stanley grew its stake in Isoray by 3,364.7% in the second quarter. Morgan Stanley now owns 76,224 shares of the healthcare company’s stock valued at $61,000 after acquiring an additional 74,024 shares during the period. 11.16% of the stock is owned by institutional investors and hedge funds.

Isoray Company Profile

IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.

Read More: Bear Market

Get a free copy of the Zacks research report on Isoray (ISR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.